- Patent Title: Modified endotoxic bacteria lipopolysaccharide (variants), combination of modified lipopolysaccharides (variants) and, containing same, a vaccine (variants) and a pharmaceutical composition (variants)
-
Application No.: US15454526Application Date: 2017-03-09
-
Publication No.: US11052142B2Publication Date: 2021-07-06
- Inventor: Petr Gennadievich Aparin , Vyacheslav Leonidovich Lvov , Stanislava Ivanovna Elkina , Marina Eduardovna Golovina , Vladimir Alekseyevich Ledov , Anna Aleksandrovna Markina , Maria Evgen'evna Shekht
- Applicant: Petr Gennadievich Aparin , Vyacheslav Leonidovich Lvov , Stanislava Ivanovna Elkina , Marina Eduardovna Golovina
- Applicant Address: RU Moscow; RU Moscow; RU Moscow; RU Moscow
- Assignee: Petr Gennadievich Aparin,Vyacheslav Leonidovich Lvov,Stanislava Ivanovna Elkina,Marina Eduardovna Golovina
- Current Assignee: Petr Gennadievich Aparin,Vyacheslav Leonidovich Lvov,Stanislava Ivanovna Elkina,Marina Eduardovna Golovina
- Current Assignee Address: RU Moscow; RU Moscow; RU Moscow; RU Moscow
- Agency: Pergament & Cepeda LLP
- Agent Milagros A. Cepeda; Edward D. Pergament
- Main IPC: A61K39/108
- IPC: A61K39/108 ; A61K39/112 ; C08B37/00 ; A61K39/02 ; A61K39/00
Abstract:
For the first time individual (free from impurities of penta- and hexa-acetylated derivatives) di-, tri- and tetra-acetylated S-LPS of endotoxic bacteria and combinations thereof were obtained and their immunobiological, physical-chemical and chemical-pharmaceutical properties were studied.
For the first time the principal possibility of their clinical application was directly demonstrated as vaccines and pharmaceutical compositions containing the modified S-LPS individual as monocomponent or combinations thereof as two and three component active substance, respectively.
The modified S-LPS and combinations thereof have high safety profile and provide low pyrogenicity and high immunogenicity. Developed on their basis vaccines and pharmaceutical compositions demonstrate anti-shock activity, high efficiency and specificity, broad-spectrum action and also good chemical-pharmaceutical parameters.
For the first time the principal possibility of their clinical application was directly demonstrated as vaccines and pharmaceutical compositions containing the modified S-LPS individual as monocomponent or combinations thereof as two and three component active substance, respectively.
The modified S-LPS and combinations thereof have high safety profile and provide low pyrogenicity and high immunogenicity. Developed on their basis vaccines and pharmaceutical compositions demonstrate anti-shock activity, high efficiency and specificity, broad-spectrum action and also good chemical-pharmaceutical parameters.
Public/Granted literature
Information query
